Lates News

Roche announced that the Phase III TALENTACE study has reached its primary endpoint. The study evaluated the efficacy and safety of atezolizumab, bevacizumab, and on-demand transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The study showed a statistically and clinically significant improvement in TACE-induced progression-free survival (TACE-PFS, defined as the time from randomization to the investigator-assessed TACE-unrecoverable progression or TACE failure/resistance, or death for any reason) at the time of the interim analysis, with overall survival (OS) data still immature. Furthermore, a clinically meaningful improvement in PFS assessed by RECIST v1.1 was also observed.